Old Road Campus

Vaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20, 2023

Retrieved on: 
Wednesday, September 13, 2023
Auckland City Hospital, KOL, MNZM, FRCP, University, MBBS, University of Auckland, Q&A, Old Road Campus, Cancer, Nuffield Department of Population Health, Doctor of Philosophy, Autoimmunity, Small RNA, Medical research, Hepatology, Patient, Immune system, Safety, Vaccitech, HBV, Nivolumab, University of Oxford, Disease, MVA, Vaccine, FRACP, Bachelor of Medicine, Bachelor of Surgery, Hepatitis, Fellow of the Academy of Medical Sciences, MD

Details are as follows:

Key Points: 
  • Details are as follows:
    To register for the event, click here .
  • The Vaccitech management team will provide a clinical overview of VTP-300, the first antigen-specific immunotherapy that has been shown to induce sustained reductions in Hepatitis B surface antigen, a marker of the disease.
  • Vaccitech is studying VTP-300, including in combination with siRNA and low-dose anti-PD-1 antibodies, as part of the search for a regimen that could lead to a potential functional cure for HBV.
  • A live Q&A session will follow the formal presentations.

Quell Therapeutics Appoints Luke Devey, BMBCh, Ph.D. as Chief Medical Officer

Retrieved on: 
Monday, November 21, 2022
Old Road Campus, University, Inflammation, Quell, GSK, Senior, Therapy, Trial of the century, Medical research, Patient, Celgene, Bachelor of Medicine, Bachelor of Surgery, Liver transplantation, Immune system, Degenerative disease, Drug development, Nuffield Department of Population Health, Secondary research, Pharmaceutical industry, Dentistry, Medicine, Immunology, Regulatory T cell, Janssen

LONDON, Nov. 21, 2022 /PRNewswire/ -- Quell Therapeutics Ltd ("Quell"), a world leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, announces the appointment of Luke Devey, BMBCh, Ph.D. as Chief Medical Officer. Dr. Devey brings to Quell significant translational science and immunology expertise from Senior Executive roles at leading pharmaceutical companies, in addition to over 15 years of clinical experience.

Key Points: 
  • LONDON, Nov. 21, 2022 /PRNewswire/ --Quell Therapeutics Ltd ("Quell"), a world leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, announces the appointment of Luke Devey, BMBCh, Ph.D. as Chief Medical Officer.
  • Dr. Devey joins Quell from Janssen Immunology where he was Vice President and Head of Translational Science.
  • "I am delighted to welcome Luke to the team at Quell at a pivotal time for the organization," said Iain McGill, Chief Executive Officer of Quell Therapeutics.
  • Luke Devey added: "Quell Therapeutics is pioneering an exciting Treg cell therapy approach to treating diseases driven by immune dysregulation.

Quell Therapeutics Appoints Luke Devey, BMBCh, Ph.D. as Chief Medical Officer

Retrieved on: 
Monday, November 21, 2022
Old Road Campus, University, Inflammation, Quell, GSK, Senior, Therapy, Trial of the century, Medical research, Patient, Celgene, Bachelor of Medicine, Bachelor of Surgery, Liver transplantation, Immune system, Degenerative disease, Drug development, Nuffield Department of Population Health, Secondary research, Pharmaceutical industry, Dentistry, Medicine, Immunology, Regulatory T cell, Janssen

LONDON, Nov. 21, 2022 /PRNewswire/ -- Quell Therapeutics Ltd ("Quell"), a world leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, announces the appointment of Luke Devey, BMBCh, Ph.D. as Chief Medical Officer. Dr. Devey brings to Quell significant translational science and immunology expertise from Senior Executive roles at leading pharmaceutical companies, in addition to over 15 years of clinical experience.

Key Points: 
  • LONDON, Nov. 21, 2022 /PRNewswire/ --Quell Therapeutics Ltd ("Quell"), a world leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, announces the appointment of Luke Devey, BMBCh, Ph.D. as Chief Medical Officer.
  • Dr. Devey joins Quell from Janssen Immunology where he was Vice President and Head of Translational Science.
  • "I am delighted to welcome Luke to the team at Quell at a pivotal time for the organization," said Iain McGill, Chief Executive Officer of Quell Therapeutics.
  • Luke Devey added: "Quell Therapeutics is pioneering an exciting Treg cell therapy approach to treating diseases driven by immune dysregulation.

Vaccitech’s VTP-300 induced sustained reductions of surface antigen in patients with chronic hepatitis B both as a monotherapy and in combination with a single low dose of anti-PD-1

Retrieved on: 
Wednesday, June 22, 2022
Hepatitis, Population, Security (finance), MVA, Old Road Campus, University of Oxford, Infection, Disease, University, Poxviridae, GLOBE, Poster, Annual report, CHB, ChAdOx1, Oxford University Innovation, Hepatology, Private Securities Litigation Reform Act, Antigen, Degenerative disease, DNA, Immune system, NASDAQ, SEC, Medical school, COVID-19, Knowledge, OXFORD, Nivolumab, OUI, Immune tolerance, Patient, Nuffield Department of Population Health, U.S. Securities and Exchange Commission, Immunotherapy, EASL, AstraZeneca, Chinese University of Hong Kong, Safety, Vaccine, Liver, Company, Cancer, Medical research, Genotype, Faculty, Autoimmunity, HBV, Pharmaceutical industry, Vaccitech, Medicine, HBsAg

OXFORD, United Kingdom, June 22, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, cancer, and autoimmune diseases, today announced an update to the interim analysis of safety and efficacy data from the HBV002 study (NCT04778904), which is being presented as a poster at the 2022 EASL International Liver CongressTM by Professor Ellie Barnes, Professor of Hepatology and Experimental Medicine at the University of Oxford.

Key Points: 
  • Meaningful, durable reductions of Hepatitis B surface antigen (HBsAg) were seen in some patients who received VTP-300 as either a monotherapy or in combination with a single low dose of nivolumab at the booster dose.
  • In the VTP-300 monotherapy group, meaningful and durable reductions of HBsAg were seen in all three patients with baseline HBsAg under 50 IU/mL.
  • These three patients had 0.7, 0.7 and 1.4 log10 declines two months after the last dose of VTP-300.
  • These dramatic declines have persisted in all three patients at their latest follow-up at five or eight months after the last dose of VTP-300.

Enara Bio and Collaborators Present Progress Towards Developing MR1-targeted T-Cell Therapies at 12th International CD1-MR1 EMBO Meeting

Retrieved on: 
Monday, May 9, 2022
Dark, MR1, Population, Immune system, University, Nuffield Department of Population Health, Cardiff University, BDI, Company, EMBO, Francis Crick Institute, Metabolomics, Professor of Genetics, University of Oxford, Research, Infection, Old Road Campus, Immunotherapy, Partnership, Ligand, Johns Hopkins School of Medicine, Cancer, Boehringer Ingelheim, 2021 Essex County Council election, European Molecular Biology Organization, RA, TCR, HLA, Science, Monash University, Pharmaceutical industry, Vaccine, Aeris Naviter AN-2 Enara, Medicine

MR1 is an unconventional antigen-presenting molecule that presents metabolites to the immune system in the context of cancer and infection.

Key Points: 
  • MR1 is an unconventional antigen-presenting molecule that presents metabolites to the immune system in the context of cancer and infection.
  • The monomorphic nature of MR1 strongly suggests that therapies based on MR1-displayed antigens could be effective across the entire human population.
  • The first presentation, from Enara scientists, highlights the progress the Company is making with its lead autologous MR1-targeting TCR-T program.
  • Enara Bio is backed by leading life science investors, including SV Health Investors, the founding investor, together with RA Capital and Samsara Biocapital.

Enara Bio and Collaborators Present Progress Towards Developing MR1-targeted T-Cell Therapies at 12th International CD1-MR1 EMBO Meeting

Retrieved on: 
Monday, May 9, 2022
Dark, MR1, Population, Immune system, University, Nuffield Department of Population Health, Cardiff University, BDI, Company, EMBO, Francis Crick Institute, Metabolomics, Professor of Genetics, University of Oxford, Research, Infection, Old Road Campus, Immunotherapy, Partnership, Ligand, Johns Hopkins School of Medicine, Cancer, Boehringer Ingelheim, 2021 Essex County Council election, European Molecular Biology Organization, RA, TCR, HLA, Science, Monash University, Pharmaceutical industry, Vaccine, Aeris Naviter AN-2 Enara, Medicine

MR1 is an unconventional antigen-presenting molecule that presents metabolites to the immune system in the context of cancer and infection.

Key Points: 
  • MR1 is an unconventional antigen-presenting molecule that presents metabolites to the immune system in the context of cancer and infection.
  • The monomorphic nature of MR1 strongly suggests that therapies based on MR1-displayed antigens could be effective across the entire human population.
  • The first presentation, from Enara scientists, highlights the progress the Company is making with its lead autologous MR1-targeting TCR-T program.
  • Enara Bio is backed by leading life science investors, including SV Health Investors, the founding investor, together with RA Capital and Samsara Biocapital.

Vaccitech’s VTP-300 was Well-Tolerated and Induced T cells against all targeted HBV antigens in both Healthy Volunteers and Patients with Chronic HBV Infection in Interim Analyses

Retrieved on: 
Friday, November 12, 2021
Safety, University, CHB, HBV, HC, Antigen, HBsAg, NASDAQ, Hepatitis, Group 2, Nivolumab, Immunotherapy, Nuffield Department of Population Health, Human, Liver, Vaccine, GLOBE, Peptide, SFU, Hepatitis B, Old Road Campus, DNA, Phase 1, Group 1, Patient, University of Oxford, Genotype, OXFORD

OXFORD, United Kingdom, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced results from ongoing Phase 1 and Phase 1b/2a clinical trials of VTP-300, an immunotherapy candidate in development for the treatment of CHB infection. Results to date showed that both the ChAdOx1-HBV (prime), in study HBV001 (healthy volunteers and CHB patients), and the combination of ChAdOx1-HBV (prime) and MVA-HBV (boost), in study HBV002 (CHB patients only), were highly immunogenic to all HBV viral targets, and were generally well tolerated. The data are available in two posters at the AASLD The Liver Meeting®.

Key Points: 
  • ChAdOx-1-HBV alone (HBV001) was well tolerated in healthy volunteers and CHB patients; VTP-300 (HBV002) was well-tolerated in CHB patients.
  • The interim results of these ongoing studies are promising in the field of HBV immunotherapy, said Thomas Evans, M.D., Chief Scientific Officer of Vaccitech.
  • Participants are healthy controls (HC) and patients with CHB with supressed HBV DNA on nucleos(t)ide therapy.
  • As in the HBV001 results, T cell responses cross-reactive to Genotype D specific peptides were measured in the majority of patients.

Vaccitech Announces Data Presentations at AASLD’s Liver Meeting® 2021

Retrieved on: 
Monday, October 18, 2021
Old Road Campus, Human, Vaccitech, Nuffield Department of Population Health, Private Securities Litigation Reform Act, HBV, Cancer, Security (finance), University of Oxford, SEC, Infection, Oxford University Innovation, Liver, ChAdOx1, OUI, GLOBE, Vaccine, U.S. Securities and Exchange Commission, MVA, Company, University, NASDAQ, Degenerative disease, AstraZeneca, COVID-19, Pharmaceutical industry

OXFORD, U.K., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced two poster presentations at AASLDs Liver Meeting 2021showcasing clinical data for VTP-300, the Companys immunotherapeutic in development for the treatment of chronic hepatitis B virus (HBV) infection.

Key Points: 
  • OXFORD, U.K., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced two poster presentations at AASLDs Liver Meeting 2021showcasing clinical data for VTP-300, the Companys immunotherapeutic in development for the treatment of chronic hepatitis B virus (HBV) infection.
  • The Liver Meeting will be held virtually on November 12-15, 2021.
  • Vaccitech co-invented a COVID-19 vaccine with the University of Oxford, now approved for use in many territories and exclusively licensed worldwide to AstraZeneca through Oxford University Innovation, or OUI.
  • Vaccitech is entitled to receive a share of the milestones and royalty income received by OUI from AstraZeneca.

University of Oxford and Oracle Cloud System Helping Researchers Identify COVID-19 Variants Faster

Retrieved on: 
Monday, September 20, 2021
Cloud, Policy, CTO, Delta, SP3, Tony Blair Institute for Global Change, University, Virus, Oracle Corporation, Program, Pathology, Java, Safety, Laboratory, Industry, Southwest Border Security Consortium, Global Health, Old Road Campus, Multimedia, Heart, CEO, Divisions of the University of Oxford, Coronavirus, TBI, Oracle Cloud, Variant of concern, NYSE, Global change, Oxford Nanopore Technologies, Solution, Institute, MySQL, Microbiology, Face, Severe acute respiratory syndrome coronavirus 2, Organization, OCI, Oxford University Innovation, Time, Nuffield Department of Population Health, Oracle Application Express, COVID-19, Public health, View, Research, University of Oxford, Lawrence, Pharmaceutical industry, Vaccine, Medical device, Software

Uniting governments and medical communities in this challenge, the University of Oxford and Oracle's Global Pathogen Analysis System (GPAS) is now being used by organizations on nearly every continent.

Key Points: 
  • Uniting governments and medical communities in this challenge, the University of Oxford and Oracle's Global Pathogen Analysis System (GPAS) is now being used by organizations on nearly every continent.
  • The Global Pathogen Analysis System is being provided as a free resource to help combat COVID-19 and other microbial health threats.
  • Researchers are using the system to upload pathogen data and receive comprehensive results within minutes.
  • Oracle offersintegrated suites of applications plus secure, autonomous infrastructure in the Oracle Cloud.For more information about Oracle (NYSE: ORCL), please visit us at oracle.com .